New hope for aggressive brain cancer: trial tests powerful drug cocktail
NCT ID NCT07185373
Summary
This study is testing whether adding one or two new drugs (orelabrutinib and teniposide) to standard chemotherapy works better for newly diagnosed primary brain lymphoma. Researchers will randomly assign 215 adults to receive different drug combinations to see which helps more patients achieve complete remission. The goal is to find more effective treatments to control this aggressive cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, Qilu Hospital of Shandong University
Jinan, China
Contact
-
West China Hospital of Sichuan University
Chengdu, China
Contact
Conditions
Explore the condition pages connected to this study.